TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20197015

Group type: EXPERIMENTAL
Intervention: Combination of normal-dose telmisartan (40 mg) and low-dose hydrochlorothiazide (12.5 mg) once daily for 12 weeks
Number of subjects: 60
Study: 17284896

Group type: EXPERIMENTAL
Intervention: Continuous infusion technique for measuring glomerular filtration rate and renal plasma flow
Number of subjects: 44
Study: 16899775

Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin per day
Number of subjects: 4731

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4731
Study: 14749513

Group type: EXPERIMENTAL
Intervention: Routine magnetic resonance (MR) imaging of the brain with a whole‐body 1.5‐T imager
Number of subjects: 9
Study: 11044062

Group type: EXPERIMENTAL
Intervention: Pulsed fluoroscopy at 15, 7.5, and 3.75 frames per second
Number of subjects: 70

Group type: COMPARATOR
Intervention: Continuous fluoroscopy
Number of subjects: 70
Study: 8834413

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 72
Study: 1291703

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 26
Study: 6377852

Group type: EXPERIMENTAL
Intervention: Cronassial (12 patients)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (13 patients)
Number of subjects: 25
Study: 28810433

Group type: EXPERIMENTAL
Intervention: non-expert group-delivered ultra-brief defusion and acceptance interventions
Number of subjects: 63

Group type: COMPARATOR
Intervention: distraction control
Number of subjects: 63
Study: 29199396

Group type: COMPARATOR
Intervention: Arm 1 (patient information)
Number of subjects: 2391

Group type: COMPARATOR
Intervention: Arm 2 (links to educational materials for diagnosis and management of pain)
Number of subjects: 2391

Group type: COMPARATOR
Intervention: Arm 3 (both patient information and links to educational materials)
Number of subjects: 2391

Group type: EXPERIMENTAL
Intervention: Arm 4 (no communication)
Number of subjects: 2391
Study: 25720557

Group type: COMPARATOR
Intervention: Concurrent neck dissection during TORS (control group)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Staged neck dissection 8.4 days after TORS (experimental group)
Number of subjects: 41
Study: 23091109

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m², thalidomide 100 mg, and dexamethasone 40 mg (VTD)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m², thalidomide 100 mg, and dexamethasone 40 mg with cyclophosphamide 400 mg/m² (VTDC)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Post-induction combined CR/nCR rates
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Three-year overall survival
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Grade 3 to 4 adverse events (AEs)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Serious AEs
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (EORTC QLQ-C30 Global Health score)
Number of subjects: 98
Study: 21723605

Group type: COMPARATOR
Intervention: Reference formulation of donepezil (10 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Test formulation of donepezil (10 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 22

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Test formulation
Number of subjects: 22
Study: 19969215

Group type: EXPERIMENTAL
Intervention: Lotrafilcon A (Night & Day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Lotrafilcon B (O(2)Optix)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both types of lenses
Number of subjects: 44
Study: 17138308

Group type: EXPERIMENTAL
Intervention: Preterm intervention
Number of subjects: 215

Group type: COMPARATOR
Intervention: Preterm control
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: ELBW infants
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 215
Study: 12653691

Group type: EXPERIMENTAL
Intervention: Caffeine-replete (200 mg caffeine capsules twice daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Caffeine-withdrawn (placebo)
Number of subjects: 11
Study: 11885175

Group type: EXPERIMENTAL
Intervention: Implants placed in augmented maxillary sinuses using various grafting materials (autogenous bone, DFDBA, HA, combination grafts)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Implants placed in the posterior maxilla without sinus grafting
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Overall implants placed
Number of subjects: 45
Study: 8807564

Group type: EXPERIMENTAL
Intervention: Mineral tablets containing calcium, potassium and sodium phosphates (Redusan Combi) during first 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (without phosphates) during next 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo first and mineral tablets in the final period (group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phosphate supplementation
Number of subjects: 30
Study: 1570233

Group type: EXPERIMENTAL
Intervention: Experimental buccal formulation of piroxicam (20 mg daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral capsules of piroxicam (20 mg daily)
Number of subjects: 10
Study: 6367129

Group type: EXPERIMENTAL
Intervention: Cefuroxime sodium (1 preincisional intraparietal infiltration along the line of proposed incision)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (same volume as cefuroxime, administered by the same route)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Antibiotic treated group (cefuroxime)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cefuroxime sodium
Number of subjects: 100
Study: 30852323

Group type: EXPERIMENTAL
Intervention: Memory Support Intervention (constructive memory support strategies)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Memory Support Intervention
Number of subjects: 44
Study: 29167351

Group type: COMPARATOR
Intervention: Stable FGF23 trajectory (n=724)
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Slowly rising FGF23 trajectory (n=486)
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Rapidly rising FGF23 trajectory (n=99)
Number of subjects: 1135
Study: 27465666

Group type: EXPERIMENTAL
Intervention: Wearing a fat suit (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not wearing a fat suit (control group)
Number of subjects: 0
Study: 24517291

Group type: EXPERIMENTAL
Intervention: Low-dose NCCT (5, 7.5, 15, 30, 50, 70, and 140 mAs)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Conventional-dose NCCT (not explicitly defined in terms of mAs)
Number of subjects: 133
Study: 22952185

Group type: EXPERIMENTAL
Intervention: Plasma α-linolenic acid (ALA)
Number of subjects: 19097

Group type: EXPERIMENTAL
Intervention: Plasma docosapentaenoic acid (DPA)
Number of subjects: 19097

Group type: EXPERIMENTAL
Intervention: Dietary marine n-3 FAs
Number of subjects: 19097

Group type: EXPERIMENTAL
Intervention: Fish intake
Number of subjects: 19097

Group type: EXPERIMENTAL
Intervention: Plasma EPA and DHA
Number of subjects: 19097
Study: 20563764

Group type: EXPERIMENTAL
Intervention: Supervised exercise sessions (3 times per week for 12 weeks)
Number of subjects: 60
Study: 17318648

Group type: EXPERIMENTAL
Intervention: 200 W cycling exercise for 15 minutes
Number of subjects: 12
Study: 16268391

Group type: EXPERIMENTAL
Intervention: Flowable resin composite (Flow Line)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Flowable compomer (Dyract Flow)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Conventional preventive resin technique (resin composite and sealant)
Number of subjects: 165
Study: 14588388

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (nonexercise)
Number of subjects: 35
Study: 9513626

Group type: EXPERIMENTAL
Intervention: Take-home medication
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Dose increase
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Counseling sessions
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Additional service items (e.g., rent, food or gas payments; employment assistance; medical care)
Number of subjects: 111
Study: 8061173

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (120 mg q.i.d.) and amoxycillin (500 mg q.i.d.)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate and amoxycillin
Number of subjects: 220
Study: 3288467

Group type: EXPERIMENTAL
Intervention: Sustained release nifedipine 20mg twice daily
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Atenolol 50mg in the morning and placebo in the evening
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Sustained release nifedipine 20mg plus atenolol 50mg in the morning and placebo in the evening
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 81
Study: 31269364

Group type: EXPERIMENTAL
Intervention: Rituximab (two infusions, 1000 mg each, administered 14 days apart; repeated at 6 months in case of partial response)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Cyclosporine (starting at a dose of 3.5 mg per kilogram of body weight per day for 12 months)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 130

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 130
Study: 28049542

Group type: EXPERIMENTAL
Intervention: Enhanced Parenting Wisely (PW+) intervention with four in-person coaching sessions, personalized text messages, and an expert-moderated online parent message board.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard Care (SC) only.
Number of subjects: 70
Study: 26169969

Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel plus gemcitabine
Number of subjects: 861

Group type: COMPARATOR
Intervention: gemcitabine alone
Number of subjects: 861
Study: 24555233

Group type: EXPERIMENTAL
Intervention: Bolus intravenous administration of cytoflavin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dropwise intravenous injection of cytoflavin
Number of subjects: 0
Study: 21240870

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate 30 mg daily, titrated to a maximum dosage of 120 mg daily for 24 weeks.
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (nitrate group)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Non-nitrate group
Number of subjects: 144
Study: 18048424

Group type: EXPERIMENTAL
Intervention: Creatine (2 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16982453

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IVIG) at a daily dose of 400 mg/kg for 2-3 times
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (routine treatment only)
Number of subjects: 121
Study: 12890051

Group type: EXPERIMENTAL
Intervention: Biphasic shocks (150 J, followed by 200 J and then 360 J if necessary)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Monophasic shocks (360 J)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Biphasic shocks after crossover from monophasic
Number of subjects: 56

Group type: COMPARATOR
Intervention: Monophasic shocks after crossover from biphasic
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Any biphasic shock at any point in the protocol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Any monophasic shock at any point in the protocol
Number of subjects: 56
Study: 11022778

Group type: EXPERIMENTAL
Intervention: SDD 10 mg qd
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SDD 20 mg qd
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SDD 20 mg bid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9205026

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 42
Study: 7525886

Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2 during every other cycle) with 5-FU (800 mg/m2/d) and HU (escalating doses) and concomitant radiotherapy (1.8 to 2.0 Gy on days 1 to 5) plus G-CSF (5 micrograms/kg/d on days 6 to 13)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 5-FU (800 mg/m2/d) and HU (escalating doses) and concomitant radiotherapy (1.8 to 2.0 Gy on days 1 to 5) without G-CSF
Number of subjects: 45
Study: 2455150

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 100
Study: 30476356

Group type: EXPERIMENTAL
Intervention: Brief or extended overdose training and injectable or nasal naloxone
Number of subjects: 39
Study: 29334437

Group type: EXPERIMENTAL
Intervention: 0.454% stabilized stannous fluoride (SnF2) dentifrice (Crest® Pro‐Health™ smooth formula)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.23% sodium fluoride (NaF) marketed control dentifrice with 5% potassium nitrate (Sensodyne® Pronamel®)
Number of subjects: 0
Study: 26120335

Group type: EXPERIMENTAL
Intervention: Kegel exercises for 8 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 79
Study: 24944257

Group type: EXPERIMENTAL
Intervention: Shared medical appointments (SMAs)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Individual outpatient appointments (control)
Number of subjects: 272
Study: 21037470

Group type: EXPERIMENTAL
Intervention: Electromagnetically visualized jejunal tube
Number of subjects: 66

Group type: COMPARATOR
Intervention: Endoscopically placed jejunal tube
Number of subjects: 66
Study: 19302707

Group type: EXPERIMENTAL
Intervention: IFN beta‐1a 44 mcg biw
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: IFN beta‐1a 44 mcg tiw
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: IFN beta‐1a 66 mcg tiw
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 17518989

Group type: EXPERIMENTAL
Intervention: Myristyl nicotinate (MN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14699200

Group type: EXPERIMENTAL
Intervention: Schizophrenia label
Number of subjects: 382

Group type: COMPARATOR
Intervention: No mental illness information provided
Number of subjects: 382
Study: 11913289

Group type: EXPERIMENTAL
Intervention: 5.3% hydrogen peroxide strip plus prebrushing
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 6.5% hydrogen peroxide strip plus prebrushing
Number of subjects: 36

Group type: COMPARATOR
Intervention: 6.5% hydrogen peroxide strip without prebrushing
Number of subjects: 36
Study: 9579257

Group type: EXPERIMENTAL
Intervention: mivacurium
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: pancuronium
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: cMP 2:1 (32 micrograms.kg-1 mivacurium + 16 micrograms.kg-1 pancuronium)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: cMP 20:1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: neostigmine 35 micrograms.kg-1
Number of subjects: 70
Study: 7695422

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (16 mmol continuously from anesthetic induction to aortic cross‐clamping, followed by 32 mmol starting after release of aortic cross‐clamp until 24 hours later)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no magnesium sulfate)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (Group A)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 98
Study: 2651597

Group type: EXPERIMENTAL
Intervention: Direct extubation from intermittent mandatory ventilation rates of six per minute
Number of subjects: 60

Group type: COMPARATOR
Intervention: Preextubation trial of continuous positive airway pressure (CPAP) of 3 cm H2O for six hours
Number of subjects: 60
Study: 1015538

Group type: EXPERIMENTAL
Intervention: Postoperative systemic BCG adjuvant immunotherapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Radical neck dissection alone
Number of subjects: 25
Study: 6992003

Group type: EXPERIMENTAL
Intervention: Ritodrine hydrochloride
Number of subjects: 0
Study: 30408205

Group type: EXPERIMENTAL
Intervention: Parent and youth intervention (Families Preparing the New Generation)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Youth only intervention (keepin'it REAL)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 462
Study: 27808588

Group type: EXPERIMENTAL
Intervention: Metformin (1500 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Myo-inositol (4 g/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study: 26395578

Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efficient biomass cookstoves
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 24114734

Group type: EXPERIMENTAL
Intervention: Dimetinden
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hydroxyzine and chlorpheniramine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 21451498

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19060617

Group type: EXPERIMENTAL
Intervention: Web-based program
Number of subjects: 35

Group type: COMPARATOR
Intervention: Written information-only control
Number of subjects: 35
Study: 17721241

Group type: EXPERIMENTAL
Intervention: Weighted spectral median frequency
Number of subjects: 40

Group type: COMPARATOR
Intervention: Median frequency
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spectral edge frequency
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bispectral Index
Number of subjects: 40
Study: 14993128

Group type: EXPERIMENTAL
Intervention: ICD (n=699)
Number of subjects: 1159

Group type: COMPARATOR
Intervention: Conventional care (n=460)
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 1159
Study: 12091045

Group type: EXPERIMENTAL
Intervention: 3.500 IU anti‐Xa of tinzaparin (Innohep) subcutaneously once daily
Number of subjects: 300

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 300
Study: 10468700

Group type: EXPERIMENTAL
Intervention: UDCA for 3 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 79
Study: 8683829

Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 2403851

Group type: COMPARATOR
Intervention: 0 ml.kg‐1 apple juice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6 ml.kg‐1 apple juice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 ml.kg‐1 apple juice
Number of subjects: 0
Study: 341903

Group type: EXPERIMENTAL
Intervention: Halopredone acetate (0.05% in cream)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fluocinonide (0.05% in cream)
Number of subjects: 16
Study: 31215425

Group type: EXPERIMENTAL
Intervention: New exercise facility
Number of subjects: 3200

Group type: COMPARATOR
Intervention: Control site (no new exercise facility)
Number of subjects: 3200
Study: 28720898

Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 40
Study: 25303988

Group type: EXPERIMENTAL
Intervention: Thromboelastometry-guided blood product management
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional blood product management
Number of subjects: 78
Study: 23745226

Group type: EXPERIMENTAL
Intervention: Test shampoo
Number of subjects: 34

Group type: COMPARATOR
Intervention: Comparative shampoo
Number of subjects: 34
Study: 21670715

Group type: EXPERIMENTAL
Intervention: Biosynthesized cellulose (BSC) duraplasty device
Number of subjects: 99

Group type: COMPARATOR
Intervention: Commercially available dural replacements (control)
Number of subjects: 99
Study: 19356750

Group type: EXPERIMENTAL
Intervention: Needle-free CO(2) injection system (Biojector 2000)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional sharp needles for gonadotropin injections
Number of subjects: 0
Study: 17078457

Group type: COMPARATOR
Intervention: Healthy internal organs
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Diseased internal organs
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 538
Study: 15276892

Group type: EXPERIMENTAL
Intervention: Computerized simulator system (ANAKIN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Training video
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (ANAKIN and Training video)
Number of subjects: 60
Study: 12471719

Group type: EXPERIMENTAL
Intervention: Test group (vegetable drink with 0.5 g of sardine peptides and 0.4 mg of VY)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (vegetable drink without sardine peptides)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Excessive ingestion test (585 g of test drink for 14 days)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Excessive ingestion test (585 g of control drink for 14 days)
Number of subjects: 63
Study: 9713632

Group type: EXPERIMENTAL
Intervention: Oxygen breathing
Number of subjects: 18

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 18

Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 18

Group type: COMPARATOR
Intervention: First test
Number of subjects: 18

Group type: COMPARATOR
Intervention: Second test
Number of subjects: 18

Group type: COMPARATOR
Intervention: Third test
Number of subjects: 18
Study: 8573948

Group type: EXPERIMENTAL
Intervention: 2-hour amphotericin B infusions
Number of subjects: 25

Group type: COMPARATOR
Intervention: 4-hour amphotericin B infusions
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment regimens
Number of subjects: 25

Group type: COMPARATOR
Intervention: Treatment regimens
Number of subjects: 25
Study: 2617169

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg o.m. + Amoxicillin 750 mg b.i.d (Group 1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Amoxicillin 750 mg b.i.d (Group 3)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Omeprazole 40 mg o.m. (Group 2)
Number of subjects: 24
Study: 321487

Group type: EXPERIMENTAL
Intervention: Indoprofen (three dose levels)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASA (three dose levels)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0